|   | |
| Names | |
|---|---|
| IUPAC name N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
|  PubChem CID | |
|  CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C31H42ClN5O3 | |
| Molar mass | 568.16 g·mol−1 | 
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
BIBN 99 is an antagonist of mACh receptors. Specifically, it is selective for the M2 type. [1]
During research, it was observed that BIBN 99 was able to diminish the cognitive deficits caused by injury. [2] Another also came to the conclusion that the compound could provide cognitive improvements. [3] The cognitive effects could possibly be caused by the increased release of acetylcholine, a neurotransmitter. [4]